Integrating Suicide Prevention Packages Into Task-shifted Mental Health Interventions in Low-resourced Contexts

Sponsor
Yale University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06094959
Collaborator
Dhulikhel Hospital, Kathmandu University School of Medical Sciences (Other), American Foundation for Suicide Prevention (Other)
36
1
16.1
2.2

Study Details

Study Description

Brief Summary

The goal of this study is to assess the feasibility and acceptability of implementing a co-designed suicide prevention package of implementation strategies (SuPP) in a pilot open, non-randomized, clinical trial. The main questions it aims to answer are:

  1. What is the feasibility of implementing the SuPP open clinical trial?

  2. What is the degree to which SuPP was implemented correctly

  3. What is the perceived acceptability of SuPP among providers and patients?

Participants will include healthcare providers and patients at risk for suicide. Providers will identify and provide culturally adapted safety planning and contact follow up to at-risk patients over a period of six months. Patients will receive an initial culturally adapted patient-centered safety plan and receive a tapered series of contacts (phone calls) over the course of six months from health providers.

Condition or Disease Intervention/Treatment Phase
  • Other: Suicide Prevention Package
N/A

Detailed Description

Low and middle income countries (LMIC) hold 75% of the world's suicides. Suicide disproportionately affects those living in poverty and in adverse conditions and, in LMIC settings, up to 20% of maternal deaths are due to suicide. In Nepal, suicide is a leading cause of death among women of reproductive age. Despite the disproportionate burden, systematic suicide detection and prevention mechanisms are nearly non-existent. Deaths are only a fraction of the burden, where evidence from Nepal reports between 5 and 27% of individuals have current thoughts of suicide. Suicidal behavior remains under-reported and is difficult for clinicians to properly identify and monitor, especially in limited health systems. This calls for improved understanding of how to identify and monitor individuals at risk for suicidal behavior. Therefore, this study seeks to integrate existing hospital healthcare providers into suicide prevention, contributing much needed evidence for multi-pronged, accessible strategies to reduce a leading cause of death worldwide.

This study's purpose is to adapt and pilot the implementation of packaged suicide prevention strategies in a low-resource setting. The impact involves informing an implementation plan to test in a fully powered future trial. Findings will contribute to the evidence of systems-integrated suicide prevention strategies and result in a multi-level package for mental health service integration that can be utilized around the world. Ultimately, this project will save lives and improve under-resourced health systems. The pilot trial is not powered for statistical analysis, but data will be monitored monthly and continuously analyzed to facilitate iterative revision, then finalization of the protocol.

The implementation package to be tested (the Suicide Prevention Package, SuPP) will include a culturally adapted suicide crisis response plan and a series of contacts via phone call from a hospital healthcare provider. This is a small open, non-randomized, pilot trial to assess the feasibility and acceptability of SuPP within the existing health system. The investigators will select delivery agents, an implementation strategy, and complete SuPP training. The investigators will train the selected delivery agents and their supervisory team (e.g., hospital nurses, physicians, and department heads) in SuPP (detection, safety planning, brief contact follow up). Participants will be recruited through the hospital's emergency department. Following suicide risk detection (e.g., suicide attempt in the past 6 months), 24 at-risk patients will be enrolled in the open trial and given the full SuPP package. All participants will receive standard of care, the SuPP package is in addition. In accordance with recommendations for pilot trial studies, The investigators have established qualitative and quantitative indicators to guide decisions about what procedures to carry through to the full trial and when modifications should be made. Each patient will be provided contact and suicide crisis response planning (weekly, then tapering to monthly) for at least 6 months. SuPP feasibility and acceptability will be determined by the following criteria: delivery agent fidelity to SuPP elements at 75% or greater; retention of at least 70% of participants through 6 months of SuPP; fewer than 15% missing items on outcome measures across all assessments; 80% of delivery agents and patients finding SuPP acceptable. In domains where criteria are met, the investigators will retain the procedure for a future full trial. In domains where criteria are not met, the investigators will modify procedures for the future full trial.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Integrating Suicide Prevention Packages Into Task-shifted Mental Health Interventions in Low-resourced Contexts
Actual Study Start Date :
May 30, 2023
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Feasibility assessed by recruitment [6 months post intervention]

    Recruitment defined as the percent of eligible participants that agree to participate

  2. Feasibility assessed by treatment adherence [6 months post intervention]

    The percent of participants that completed one session with the intervention delivery agent

  3. Feasibility assessed by treatment adherence- SuPP [6 months post intervention]

    Treatment adherence defined as the percent of participants who remain in SuPP

  4. Feasibility assessed by retention [6 months post intervention]

    The percent of participants who completed all follow up measures

  5. Feasibility assessed by retention- missing items [6 months post intervention]

    The percent of missing measure items per participant

  6. Feasibility assessed by screening [6 months post intervention]

    The number of participants screened and referred

  7. Percent enrolled [6 months post intervention]

    The percent of referred participants that enrolled

  8. Median number of sessions completed [6 months post intervention]

    Median number of sessions completed

Secondary Outcome Measures

  1. Acceptability assessed by Consolidated Framework for Implementation Research (CFIR) qualitative interviews [6 months post intervention]

    CFIR interviews are qualitative interviews that will be thematically analyzed with qualitative analysis guided by the CFIR framework and taxonomy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria (healthcare workers):
  • Be older than 18 at the time of recruitment

  • Speak Nepali fluently

  • Be actively employed by Dhulikhel Hospital/KUSMS

  • Have a valid certificate of practice from the Ministry of Health and Population

Exclusion Criteria (healthcare workers)

  • Have less than 3 months of experience in current position

  • Be planning to remain in the study area or current position for less than six months

  • Be unable to provide voluntary informed consent for any reason

Inclusion Criteria (trial patients):
  • Speak Nepali fluently

  • Be older than 18 at the time of recruitment

  • Be actively receiving care from a KUDH clinician

  • Permanently reside in Dhulikhel District

  • Have access to a cell phone

  • Screen positive for suicide risk

Exclusion Criteria (trial patients):
  • Reside outside of the catchment area

  • Be planning to leave relocate their residence in the next 6 months

  • Unable to provide voluntary informed consent for any reason

  • Unable to provide a mobile phone number for contact

  • Present evidence of active and untreated mania or psychosis that could interfere with the participant's ability to volitionally consent to research or interfere with their ability to safely and reliably complete research

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dhulikhel Hospital Dhulikhel Nepal

Sponsors and Collaborators

  • Yale University
  • Dhulikhel Hospital, Kathmandu University School of Medical Sciences
  • American Foundation for Suicide Prevention

Investigators

  • Principal Investigator: Ashley Hagaman, PhD, Yale University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT06094959
Other Study ID Numbers:
  • 2000029480
  • No NIH funding
First Posted:
Oct 23, 2023
Last Update Posted:
Oct 23, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 23, 2023